ALK and non-small cell lung carcinoma: Kim et al. have published results from the ongoing phase II, randomized, open-label, multicenter international study (ALK in Lung Cancer Trial of brigatinib; ALTA, ClinicalTrials.gov identifier: NCT02094573) that evaluated the efficacy and safety of two different brigatinib dosage regimens (90 mg daily and 180 mg daily) in crizotinib-treated ALK+ locally advanced or metastatic NSCLC patients [16].